{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:37:49Z","timestamp":1771659469227,"version":"3.50.1"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Laron syndrome (LS) is a rare autosomal recessive disorder characterized by dwarfism and typical facial phenotype. This report is the first to present three cases of Laron syndrome affecting three female siblings from Syria. The index case presented at age of 8.5 years with severe short stature: low level of Insulin-like growth factor 1 (IGF-1), elevated levels of fasting and post-stimulation growth hormone (GH), consistent with the diagnosis of Laron syndrome. At the age of 9.5 years, she developed non-autoimmune subclinical hypothyroidism treated with Levothyroxine, then she developed dyslipidemia at the age of 11.3 years. Later, we identified two female siblings of the patient with Laron syndrome. Laron syndrome is a rare genetic disease, reporting of new cases of this rare syndrome must encourage pediatricians to develop high clinical suspicion if faced with patients with very short stature and typical facial features.<\/jats:p>","DOI":"10.1093\/omcr\/omab079","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T10:59:07Z","timestamp":1631530747000},"source":"Crossref","is-referenced-by-count":4,"title":["Laron syndrome in three female siblings with the development of subclinical hypothyroidism and dyslipidemia in one case: first report of a Syrian family"],"prefix":"10.1093","volume":"2021","author":[{"given":"Ahmad","family":"Chreitah","sequence":"first","affiliation":[{"name":"Department of Pediatric, Tishreen University Hospital, Lattakia, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kheria","family":"Hijazia","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Tishreen University Hospital, Lattakia, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leen Jamel","family":"Doya","sequence":"additional","affiliation":[{"name":"Department of Pediatric, Tishreen University Hospital, Lattakia, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"2021091310552371100_ref1","first-page":"1","article-title":"Laron syndrome\u2014a historical perspective","volume":"1","author":"Laron","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"2021091310552371100_ref2","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4158\/EP15939.RA","article-title":"Lessons from 50 years of study of Laron syndrome","volume":"12","author":"Laron","year":"2015","journal-title":"Endocrine Pract"},{"key":"2021091310552371100_ref3","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/jcem.84.12.6255","article-title":"The essential role of IGF-1: lessons from the long term study and treatment of children and adults with Laron syndrome","volume":"84","author":"Laron","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2021091310552371100_ref4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/1752-1947-5-301","article-title":"Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism","volume":"5","author":"Oana","year":"2011","journal-title":"J Med Case Rep"},{"key":"2021091310552371100_ref5","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/ccr3.1193","article-title":"Mexican case report of a never treated Laron syndrome patient evolving to metabolic syndrome, type 2 diabetes, and stroke","volume":"5","author":"Inma","year":"2017","journal-title":"Clin Case Rep"},{"key":"2021091310552371100_ref6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12098-007-0159-y","article-title":"Laron\u2019s syndrome in two siblings","volume":"74","author":"Chakraborty","year":"2007","journal-title":"Indian J Pediatr"},{"key":"2021091310552371100_ref7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40618-015-0327-2","article-title":"Growth hormone insensitivity: diagnostic and therapeutic approaches","volume":"39","author":"Kurtoglu","year":"2016","journal-title":"J Endocrinal Invest"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/9\/omab079\/40352713\/omab079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/9\/omab079\/40352713\/omab079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T10:59:14Z","timestamp":1631530754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omab079\/6369263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":7,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omab079","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2021,9,1]]},"article-number":"omab079"}}